Genmab A/S (GMAB)
| Market Cap | 17.95B |
| Revenue (ttm) | 3.65B |
| Net Income (ttm) | 1.37B |
| Shares Out | 61.50M |
| EPS (ttm) | 21.62 |
| PE Ratio | 1.35 |
| Forward PE | 20.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,385,037 |
| Open | 29.04 |
| Previous Close | 29.03 |
| Day's Range | 28.83 - 29.20 |
| 52-Week Range | 17.24 - 33.65 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 41.17 (+41.33%) |
| Earnings Date | Nov 6, 2025 |
About GMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price target is $41.17, which is an increase of 41.33% from the latest price.
News
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...
Why Is Genmab Stock Trading Lower On Monday?
On Saturday, Genmab A/S (NASDAQ:GMAB) revealed updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in heavily pretreated patients with advanced endom...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigati...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
Company Announcement Net sales of DARZALEX ® in the third quarter of 2025 totaled USD 3,672 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...
Genmab A/S (GMAB) M&A Call Transcript
Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimen...
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...
This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.
Genmab will acquire Merus in an all-cash transaction worth around $8 billion.
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline
Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants t...
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDT Company Participants Anthony Pagano - Executive VP & CFO Conference Call Participants Sachin Jain - B...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Mar...
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
Genmab is rated BUY due to strong royalty income, surging drug sales, and a robust late-stage oncology pipeline. GMAB's H1 2025 revenue rose 19%, driven by Darzalex royalties and rapid growth in self-...
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for bl...
Genmab: A Matter Of Time
Genmab raised the full-year revenue and operating income guidance after strong Q2 results, driven by robust royalty streams and growing net sales of Epkinly and Tivdak. Genmab's maturing and expanding...
Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Genmab A/S (GMAB) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The inc...
10 stocks to consider if you want alternatives to the expensive S&P 500
Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will part...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesute...
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...